Ligand Prescribed drugs Included (LGND) M&A Name Transcript

Operator

Girls and gents, thanks for standing by. My title is Krista, and I will likely be your convention operator immediately. At the moment, I wish to welcome everybody to Ligand Prescribed drugs to accumulate XOMA Royalty. [Operator Instructions]

I might now like to show the convention over to Melanie Herman, Head of Investor Relations. Melanie, please go forward.

Melanie Herman

Good morning, everybody, and welcome to Ligand’s investor name highlighting the announcement of our Acquisition of XOMA Royalty. Right here with me immediately are Ligand’s CEO, Todd Davis; Chief Monetary Officer, Tavo Espinoza; and Vice President of Portfolio Technique and Investments, Lauren Hay.

At this time, we’ll be discussing sure non-GAAP monetary measures, and a few of these will likely be forward-looking. We would prefer to refer you to the secure harbor assertion in these forward-looking statements, that are topic to dangers and uncertainties. Precise outcomes or occasions could differ from these projected or mentioned, and all forward-looking statements are based mostly on our present accessible info. Ligand assumes no obligation to replace these statements.

And with that, I’ll now flip the decision over to our CEO, Todd Davis.

Todd Davis
CEO & Director

Thanks, Melanie, and good morning. At this time, Ligand introduced that it has entered right into a definitive settlement to accumulate XOMA Royalty Company. Now we have recognized the XOMA crew and have been impressed with the strong portfolio of biopharmaceutical property that they’ve established